What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

To evaluate the efficacy of INBRX-106 as a hexavalent OX40 agonist in enhancing T cell activation and anti-tumor responses.

November 25, 2025The Journal of ImmunologyOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase I/II trial shows INBRX-106 improves T cell activation and boosts anti-tumor immunity, suggesting greater efficacy in clinical settings.

To evaluate the efficacy of INBRX-106 as a hexavalent OX40 agonist in enhancing T cell activation and anti-tumor responses.
Developed hexavalent OX40 agonist (INBRX-106) to improve receptor clustering.
Conducted phase I/II clinical trial (NCT04198766) with flow cytometry assessments.
Evaluated T cell proliferation and activation post-treatment with INBRX-106 and aPD-1.
Observed increased effector and memory T cell proliferation (Ki-67) with INBRX-106 treatment.
Noted enhanced activation markers (CD38+HLA-DR+) in treatment cohorts.
Single-cell RNA-seq analysis revealed increased granzyme B expression post-treatment.

Holay et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase I/II trial shows INBRX-106 improves T cell activation and boosts anti-tumor immunity, suggesting greater efficacy in clinical settings.